Kliniken & Institute ... Kliniken Zentrum für Kinder- und... Welcome Research Pediatric Oncology,... Osteosarcoma

Osteosarcoma

Roth/Blattmann/Kulozik Research Group

Cooperation partners:   Opens external link in new windowDepartment of Radiooncology and Opens external link in new windowDepartment of Orthopedics.


I.  Research areas

The working group investigates the therapeutic use of modern radiation therapy  Opens internal link in new windowOSCAR using heavy ions and protons alone and in combination with epigenetically effective agents in the treatment of osteosarcoma. One priority is to develop new treatment strategies at the pre-clinical level, but close to the patient, in order to translate them quickly into clinical trials. To this end, the working group has established a primary tumor mouse model and cooperates closely with the Heidelberg Ion-Beam Therapy Center (Opens external link in new windowHIT) and the National Center for Tumor Diseases (Opens external link in new windowNCT).


II.  Staff

Claudia Blattmann

Eva Roth

Andreas Kulozik


III. Project funding

Opens external link in new windowDietmar Hopp Foundation

Opens external link in new windowGerman Cancer Aid (Deutsche Krebshilfe)

Heidelberg University Hospital


IV.  Publications

Blattmann C, Thiemann M, Stenzinger A, Christmann A, Roth E, Ehemann V, Debus J, Kulozik AE, Weichert W, Huber PE, Oertel S, Abdollahi A.( 2013). Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. Strahlenther Onkol. 2013 Nov;189(11):957-66. doi:10.1007/s00066-013-0372-8. Epub 2013 Jun 27.

Blattmann C, Oertel S, Thiemann M, Weber KJ, Schmezer P, Zelezny O, Lopez Perez R, Kulozik AE, Debus J and Ehemann V (2012). Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. Strahlentherapie & Onkologie, 2012 Feb;188(2):168-76.  

Oertel S, Thiemann M, Richter K, Weber KJ, Huber PE, Perez RL, Brons S, Bischof M, Kulozik AE, Ehemann V, Debus J and Blattmann C. Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol. 2011 Sep 20;6:119.

Blattmann C and Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, Unterberg A, Karapanagiotou-Schenkel I, Combs SE, Nikoghosyan A, Bischof M, Jäkel O, Huber PE, Kulozik AE and Debus J (2010). Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.  BMC Cancer 10:96. 

Blattmann C and Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J and Weber KJ (2010). Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma by histone deacetylase inhibition.  Int J Radiol Biol Phys 78(1):237-45.

Oertel S and  Blattmann C, Rieken S, Jensen A, Combs SE, Huber PE, Bischof M, Kulozik AE, Debus J, Schulz-Ertner D (2010). Radiotherapy in the Treatment of primary Osteosarcoma – a single center experience. Tumori 96:582-588.

Oertel S, Thiemann M, Richter K,  Weber KJ, Huber PE, Lopez Perez R, Brons S, Bischof M, Kulozik AE, Ehemann V, Debus J, Blattmann C (2011). Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol 20;6(1):119. 

 

Click  here for a list of all Blattmann publications.